It’s earnings season again. Biogen offered a look at its second foray into Alzheimer’s disease during its investor call, but listeners were still left dubious. All eyes—and ears—are on whether its lecanemab partnership with Eisai can outperform the ill-fated Aduhelm. In this episode, we chat about what went down during the earnings presentation, including rumors of a shaky relationship between the two drugmakers.

We also explore AstraZeneca finally claiming an FDA approval for its long-troubled cancer immunotherapy Imjudo. The CTLA-4 drug has failed more than a few trials among different tumors over the years, and, now, it will enter a crowded and highly competitive liver cancer market. 

• UPDATED: Biogen insists Eisai relationship 'solid' as questions remain over lecanemab commercialization
• Despite Aduhelm cost cuts, Biogen still has Alzheimer's manufacturing firepower on deck, CFO says
• AstraZeneca's Imjudo finally snags first approval—only in an ever-crowded liver cancer field
• AIDS advocacy group hits out at 'Greediad' Gilead for drug pricing hikes
• J&J's BCMA bispecific Tecvayli wins FDA approval in multiple myeloma—but as a late-line therapy
• Medtronic to spin out respiratory, patient monitoring divisions amid flagging ventilator sales
• Sumitomo nets Myovant in $2.9B buyout, adding IVF asset to pipeline

"The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

See omnystudio.com/listener for privacy information.